Anika Therapeutics
ANIK
159 hedge funds and large institutions have $505M invested in Anika Therapeutics in 2015 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 68 increasing their positions, 49 reducing their positions, and 15 closing their positions.
89% more call options, than puts
Call options by funds: $2.42M | Put options by funds: $1.28M
39% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 49
5% more capital invested
Capital invested by funds: $483M → $505M (+$22.1M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 15
1% less funds holding
Funds holding: 160 → 159 (-1)
Top Buyers
Top Sellers
| 1 |
Millennium Management
New York
|
-$4.86M |
| 2 |
Renaissance Technologies
New York
|
-$4.05M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$3.71M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$3.48M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$3.47M |
ANIK Hedge Fund Activity: Q1 2015 in Review
159 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q1 2015, worth a combined $505M — up 4.6% from $483M a quarter earlier.
Fund positioning in ANIK was balanced in Q1 2015: 15 funds opened new positions, 15 closed out, 68 added to existing stakes and 49 trimmed.
The largest buyer was Lombardia Capital Partners, adding an estimated $24.2M. The largest seller was Millennium Management, cutting an estimated $4.86M.
- 159 institutional investors held Anika Therapeutics (ANIK) as of Q1 2015, down from 160 in Q4 2014.
- Funds reported $505M of Anika Therapeutics stock for Q1 2015, up 4.6% quarter-over-quarter.
- 15 funds opened new Anika Therapeutics positions in Q1 2015 and 15 closed out, a net change of 0 holders.
- The largest Anika Therapeutics buyer in Q1 2015 was Lombardia Capital Partners, an estimated $24.2M added.
- The largest Anika Therapeutics seller in Q1 2015 was Millennium Management, an estimated $4.86M sold.
Based on aggregated 13F filings for Q1 2015.